Starting Treatment With Agonist Replacement Therapies (START)

November 9, 2016 updated by: Walter Ling, University of California, Los Angeles
The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a randomized, open-label, multi-center, Phase 4 study to assess the changes in liver enzymes related to treatment with buprenorphine/naloxone (BUP/NX) and methadone (MET) in participants entering opioid agonist treatment. Randomization will be stratified, within site, according to normal versus abnormal screening liver function tests. Participants meeting entry criteria will be dosed for 24 weeks during the active phase of the study with assessment of liver function at weeks 1, 2, 4, 8, 12, 16, 20, 24 and with follow-up assessments at week 32. Clinicians will be encouraged to treat with adequate doses of BUP/NX and MET.

Study Type

Interventional

Enrollment (Actual)

1269

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90016
        • Matrix Institute
      • Sacramento, California, United States, 95816
        • Bi-Valley Medical Clinic INC.
      • San Francisco, California, United States, 94102
        • BAART; Turk Street Clinic
    • Connecticut
      • Hartford, Connecticut, United States, 06120
        • Hartford Dispensary
      • Waterbury, Connecticut, United States, 06705
        • CT Counseling Centers
    • New York
      • Brooklyn, New York, United States, 11201
        • Addiction Research & Treatment Corp
    • Oregon
      • Portland, Oregon, United States, 97214
        • CODA-Research
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19137
        • NET Steps
    • Washington
      • Seattle, Washington, United States, 98134
        • Evergreen Treatment Services

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Were age 18 years or older,
  2. Met DSM-IV-TR criteria for opioid dependence,
  3. Were in good general health, or, in case of a medical/psychiatric condition requiring ongoing treatment, were under the care of a physician willing to continue participant's medical management and cooperate with study physicians,

  4. For female participants, use of one of the following acceptable methods of birth control:

    1. oral contraceptives
    2. barrier (diaphragm or condom) with spermicide
    3. IUD
    4. intrauterine progesterone contraceptive system
    5. levonorgestrel implant
    6. medroxyprogesterone acetate contraceptive injection
    7. contraceptive transdermal patch
    8. hormonal vaginal contraceptive ring
    9. surgical sterilization
    10. complete abstinence from sexual intercourse
  5. Able to read and verbalize understanding of the study and voluntarily sign study informed consent form.

Exclusion Criteria:

  1. ALT or AST values > 5 times the upper limit of normal as per testing laboratory range criteria,
  2. ALP values >3 times the upper limit of normal per testing laboratory criteria,
  3. Any documented past or present history of ascites, presence of esophageal or gastric varices, hepatic encephalopathy or other signs of significant liver disease as indicated by a Model for Endstage Liver Disease score (Kamath et al., 2001) of ≥11,
  4. Total bilirubin > 2.0 mg/dl (participants with documented Gilbert's syndrome were not excluded based on this criterion),
  5. Prothrombin time more than 3 seconds prolonged,
  6. Albumin level less than 2.5 g/dl,

  7. Any cardiopathy or risk factor listed below without evidence of a normal ECG* with report performed within 6 months prior to first study medication dose,

    1. Congestive heart failure
    2. Left ventricular hypertrophy
    3. Bradycardia
    4. Hereditary QT prolongation
    5. Uncorrected electrolyte imbalance
    6. Concomitant medications that are known to have a risk of QT interval prolongation; refer to Appendix D for a list of medications.

    Note: The list was not all-inclusive.

    *An ECG was abnormal if one or more of the following occurred:

    Significant ST segment abnormalities:

    • ST segment elevations in two or more continuous leads of > 0.1 mV
    • ST segment depression of greater than 1 mm that are flat or down-sloping at 80 msec after the J point ST segment abnormalities identified as "non-specific" are acceptable. If a potential participant's ECG indicated ST segment elevations or depression consistent with ischemia, the physician obtained a medical history of cardiac symptoms and referred the participant for evaluation.

    Conduction abnormalities:

    • Mobitz II 2nd degree or 3rd degree heart block
    • Atrial fibrillation, atrial flutter, or any non-sinus tachyarrhythmia
    • Three or more consecutive ectopic ventricular complexes at a rate of > 100 per minute.
    • QTc greater than 450 msec in men and 480 msec in women

    Repolarization abnormalities:

    • Acute medical condition that would make participation, in the opinion of the study physician, medically hazardous (e.g., unstable pancreatic, cardiovascular or renal disease, significant anemia)

  8. Known allergy or sensitivity to BUP, naloxone or MET or to any of the inactive ingredients in the study medications (including lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate, FD&C Yellow No.6 color, magnesium stearate, Acesulfame K sweetener)
  9. Known diagnosis of acute psychosis, severe depression or imminent suicide risk as determined via clinical interview by study physician or surrogates
  10. DSM-IV diagnosis of dependence on alcohol requiring immediate medical attention.
  11. DSM-IV diagnosis of dependence on benzodiazepines requiring immediate medical attention
  12. DSM-IV diagnosis of dependence on other depressants, or stimulants requiring immediate medical attention
  13. Participation in an investigational drug study within the past 30 days
  14. Treatment with MET, BUP/NX, or BUP for more than 15 of the past 30 days (illicit use of these medications is allowed)
  15. Pending legal action that could prohibit study participation
  16. Unable or unwilling to comply with study requirements
  17. Unable or unwilling to remain in the local area for duration of treatment
  18. Poor venous access such that venipuncture could not be accomplished from a vein in an extremity during eligibility
  19. Pregnant or lactating (females only)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Buprenorphine/Nx
For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
Drug: Buprenorphine/naloxone
Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
Active Comparator: Methadone
For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
Drug: Methadone
Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hepatic Safety
Time Frame: 24 Weeks

Participants were categorized according liver transaminase (ALT, AST) levels in blood comparing the baseline sample to any and all subsequent samples in the following manner:

A: both ALT and AST started at less than or equal to two times the ULN and remained at two times or less ULN throughout the study

B: either ALT or AST started at less than or equal to 2 x ULN and at any point in study exceeded 2 x ULN

C: Either ALT or AST started > 2 x ULN, decreased (both ALT and AST) to < 2 x ULN, and remained < 2 x ULN

D: Either ALT or AST started > 2 x ULN and remained above 2 x ULN throughout the study
24 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, Los Angeles

Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Andrew Saxon, M.D., University of Washington

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2006

Primary Completion (Actual)

August 1, 2010

Study Completion (Actual)

August 1, 2010

Study Registration Dates

First Submitted

April 16, 2006

First Submitted That Met QC Criteria

April 16, 2006

First Posted (Estimate)

April 18, 2006

Study Record Updates

Last Update Posted (Estimate)

January 6, 2017

Last Update Submitted That Met QC Criteria

November 9, 2016

Last Verified

November 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIDA-CTN-0027
  • U10DA013045 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Opiate-related Disorders

Clinical Trials on Buprenorphine/naloxone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe